ITMI20081862A1 - COMPOSITION FOR TOPIC USE FOR THE TREATMENT OF LOCALIZED ADIPOSITIES AND RELATED IMAGINATIONS - Google Patents
COMPOSITION FOR TOPIC USE FOR THE TREATMENT OF LOCALIZED ADIPOSITIES AND RELATED IMAGINATIONS Download PDFInfo
- Publication number
- ITMI20081862A1 ITMI20081862A1 IT001862A ITMI20081862A ITMI20081862A1 IT MI20081862 A1 ITMI20081862 A1 IT MI20081862A1 IT 001862 A IT001862 A IT 001862A IT MI20081862 A ITMI20081862 A IT MI20081862A IT MI20081862 A1 ITMI20081862 A1 IT MI20081862A1
- Authority
- IT
- Italy
- Prior art keywords
- treatment
- localized
- imaginations
- composition
- phosphatidiicoline
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 11
- 238000011282 treatment Methods 0.000 title claims description 10
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 10
- 208000023184 Body fat disease Diseases 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 7
- 229960003964 deoxycholic acid Drugs 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 12
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 229940009976 deoxycholate Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000001632 homeopathic effect Effects 0.000 description 3
- 230000002366 lipolytic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007443 liposuction Methods 0.000 description 2
- 238000000694 mesotherapy Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Description
DESCRIZIONE DEL BREVETTO DI INVENZIONE INDUSTRIALE AVENTE COME DESCRIPTION OF THE INDUSTRIAL INVENTION PATENT HAVING AS
TITOLO : TITLE :
Composizioni ad uso topico per il trattamento delle adiposità localizzate e dei relativi inestetismi . Topical compositions for the treatment of localized adiposity and related imperfections.
DESCRIZIONE DESCRIPTION
Parte 1 : introduzione Part 1: introduction
Per adiposità localizzate si intende l accumulo di grasso (=cellule adipose), specialmente in alcune parti del corpo come parete addominale, glutei e cosce, con danno estetico anche notevole. Localized adiposity means the accumulation of fat (= fat cells), especially in some parts of the body such as the abdominal wall, buttocks and thighs, with even considerable aesthetic damage.
Ciò avviene a seguito di_ abitudini alimentari errate ( dieta ipercalorica, con_ conseguente tendenza all’ obesità ), sedentarietà e carenza di attività fisica, ma anche in seguito ad un intervento chirurgico, oppure ad una gravidanza. This occurs as a result of incorrect eating habits (high-calorie diet, resulting in a tendency to obesity), a sedentary lifestyle and lack of physical activity, but also following surgery, or a pregnancy.
La tendenza ad_accumulare grasso aumenta, comunque, in funzione dell’ età, disquilibri ormonali ( iperandrogenismo nella donna ), di alterazioni metaboliche { sindrome metabolica, iperinsulinismo, diabete di tipo 2 ). The tendency to accumulate fat increases, however, as a function of age, hormonal imbalances (hyperandrogenism in women), metabolic alterations (metabolic syndrome, hyperinsulinism, type 2 diabetes).
Parte 2 : le tecniche precedenti Part 2: the previous techniques
I trattamenti di comune impiego per la rimozione delle adiposità localizzate sono : The treatments commonly used for the removal of localized adiposity are:
- L’ intervento chirurgico o liposuzione. Avviene in anestesia locale e consiste in una vera e propria aspirazione mediante cannula del grasso in eccesso, - Surgery or liposuction. It takes place under local anesthesia and consists of a real aspiration through a cannula of excess fat,
- La mesoterapia. Somministrazione intradermica di principi attivi omeopatici e non, comunque in dosi molto basse,grazie all’ uso di appositi aghi. - Mesotherapy. Intradermal administration of homeopathic and non-homeopathic active ingredients, in any case in very low doses, thanks to the use of special needles.
- L’ intralipoterapia, Si tratta della somministrazione localizzata, per via iniettiva, di principi attivi lipolitici. Nello specifico : fosfatidilcolina e sodio desossicolato. - Intralipotherapy, This is the localized administration, by injection, of lipolytic active ingredients. Specifically: phosphatidylcholine and sodium deoxycholate.
- L' uso di prodotti cosmetici a base di fosfatidilcolina o, molto più spesso, di fosfatidilcolina idrogenata. - The use of cosmetic products based on phosphatidylcholine or, much more often, hydrogenated phosphatidylcholine.
In ogni caso possono costituire un utile complemento massaggi e attività fisica, unitamente ad una dieta appropriata. In any case, massages and physical activity can be a useful complement, together with an appropriate diet.
Parte 3 inconvenienti delie tecniche precedenti. Part 3 drawbacks of previous techniques.
La liposuzione comporta tutti i rischi di un vero e proprio intervento chirurgico, anche se questi possono e.ssere minimizzati ricorrendo a professionisti qualificati e_ a strutture idonee debitamente atrezzate. Le precauzioni da adottare e gli strumenti da impiegare rendono comunque il trattamento piuttosto costoso. Liposuction involves all the risks of a real surgery, even if these can be minimized by resorting to qualified professionals and suitable structures duly equipped. However, the precautions to be taken and the tools to be used make the treatment rather expensive.
La mesoterapia può causare edemi e irritazioni locali. Mesotherapy can cause local edema and irritation.
Inoltre Γ assorbimento di farmaci per via intradermica è lento, specie se i dosaggi sono bassi. Se il preparato utilizzato è infine di natura omeopatica, non esiste Γ avallo della medicina ufficiale. Furthermore, intradermal absorption of drugs is slow, especially if the dosages are low. If the preparation used is finally of a homeopathic nature, there is no Γ endorsement of official medicine.
L’ intralipoterapia non è pure priva di effetti indesiderati : oltre a fenomeni transitori dì gonfiore e arrossamento locale, alcuni autori rilevano vere e proprie alterazioni istologiche, riconducibili a fibrosi_e necrosi sia del tessuto adiposo che di quello vascolare.. In caso di trattamento a lungo termine si può anche determinare la formazione di cisti, con ovvie conseguenze di tipo estetico. Intralipotherapy is also not without undesirable effects: in addition to transient phenomena of local swelling and redness, some authors detect real histological alterations, attributable to fibrosis and necrosis of both adipose and vascular tissue. In case of long-term treatment term can also determine the formation of cysts, with obvious consequences of an aesthetic nature.
Schuller- Petrovic.S e coll. Schuller- Petrovic.S and coll.
Tissue toxic effects of phosphatidylcholine/deoxycholate after subcutaneous injection for fat dissolution in rats and human volunteers. Tissue toxic effects of phosphatidylcholine / deoxycholate after subcutaneous injection for fat dissolution in rats and human volunteers.
Derm Surg.2008 Apr; 34(4): 529-42. Derm Surg. 2008 Apr; 34 (4): 529-42.
L’ impiego di preparazioni cosmetiche è, grazie alle modalità applicative (=uso esterno), praticamente privo di effetti collaterali significativi. The use of cosmetic preparations is, thanks to the application methods (= external use), practically free of significant side effects.
Il frequente ricorso, tuttavia, alla sola fosfatidilcolina idrogenata, che risulta cosmetologicamente più accettabile perché .protegge il mantello idrolipidico cutaneo, solleva dubbi sulla reale efficacia di questi prodotti. Solo la fosfatidilcolina NON idrogenata sembrerebbe in grado di penetrare attraverso la cute e di raggiungere così i depositi di grasso. Questa azione, d’ altro canto, danneggerebbe lo strato superficiale dell’ epidermide, aumentando la perdita di acqua per evaporazione. Frequent use, however, of hydrogenated phosphatidylcholine alone, which is cosmetologically more acceptable because it protects the skin's hydrolipidic mantle, raises doubts about the real effectiveness of these products. Only NON-hydrogenated phosphatidylcholine would appear to be able to penetrate through the skin and thus reach fat deposits. This action, on the other hand, would damage the surface layer of the epidermis, increasing the loss of water by evaporation.
Handbook of Cosmetic Science and Technology, p. 155-163 Edited by A.O. Borei, M. Paye and H.l. Maibach Handbook of Cosmetic Science and Technology, p. 155-163 Edited by A.O. Borei, M. Paye and H.l. Maibach
CRC Press Taylor & Francis Group, Boca Raion 2006 Kosmetic International 1999(1), 104-106. CRC Press Taylor & Francis Group, Boca Raion 2006 Kosmetic International 1999 (1), 104-106.
Anche la fosfatidilcolina NON idrogenata, se non combinata col desossicolato, non garantirebbe comunque una sufficiente attività lipolitica, al fine di dissolvere le adiposità localizzate. Even NON-hydrogenated phosphatidylcholine, if not combined with deoxycholate, would still not guarantee sufficient lipolytic activity, in order to dissolve localized adiposities.
Salti G. e coll. Salti G. and coll.
Phosphatidylchoijne and Sodium Deoxycholate in thè treatment of localized fat_: a double-blind, randomized study. Dermatol Surg 2008 Jan;34{1 ):60-66. Phosphatidylchoijne and Sodium Deoxycholate in the treatment of localized fat_: a double-blind, randomized study. Dermatol Surg 2008 Jan; 34 {1): 60-66.
In conclusione : mentre le tecniche invasive ( chirurgiche ed iniettive ) pongono più che altro problemi di reazioni avverse, quelle non invasive { cosmetiche ) rischiano di non garantire una sufficiente efficacia. In conclusion: while invasive techniques (surgical and injection) pose more problems of adverse reactions, non-invasive ones (cosmetic) risk not guaranteeing sufficient efficacy.
Parte 4 : vantaggi dell’ invenzione Part 4: advantages of the invention
Scopo della presente invenzione.è quello di mettere a disposizione delle utilizzatrici e degli utilizzatori un trattamento non invasivo per le adiposità localizzate ed i relativi in estetismi. Tale trattamento è basato su preparazioni dermatologiche per uso topico, che abbinino in maniera ottimale tollerabilità ed efficacia. Si vogliono in particolare minimizzare gli effetti indesiderati della fosfatidilcolina NON idrogenata sul mantello idrolipidico che protegge fisiologicamente Γ epidermide. The purpose of the present invention is to provide users with a non-invasive treatment for localized adiposity and related aesthetic problems. This treatment is based on dermatological preparations for topical use, which optimally combine tolerability and efficacy. In particular, we want to minimize the undesirable effects of NON-hydrogenated phosphatidylcholine on the hydrolipidic mantle which physiologically protects the epidermis.
Come già accennato, la fosfatidilcolina NON idrogenata deteriora questo sistema di protezione naturale,aumentando sensibilmente le perdite d’ acqua per evaporazione e determinando così secchezza cutanea. As already mentioned, NON-hydrogenated phosphatidylcholine deteriorates this natural protection system, significantly increasing water losses due to evaporation and thus causing skin dryness.
Parte 5 : il concetto inventivo Part 5: the inventive concept
Si è trovato che l associazione di fosfatidilcolina _NON idrogenata, acido desossicolico e/o suoi sali e fosfatidilcolina idrogenata è risultata particolarmente efficace nel trattamento topico delle adiposità localizzate e degli in estetismi ad esse riconducibili. It has been found that the combination of NON-hydrogenated phosphatidylcholine, deoxycholic acid and / or its salts and hydrogenated phosphatidylcholine was found to be particularly effective in the topical treatment of localized adiposities and of the imperfections attributable to them.
Le composizioni oggetto_della presente invenzioni mostrano risultati non spiegabili con la semplice sommatoria degli effetti registrati con la somministrazione separata dei singoli componenti. Questo sembra apparentemente dovuto alla azione idratante indiretta della fosfatidilcolina idrogenata. Tale sostanza, al contrario della fosfatidilcolina NON idrogenata, preserva, stabilizzandolo, il mantello idrolipidico superficiale della pelle, In questo modo si minimizza la perdita d’ acqua per evaporazione, garantendo alla cute un livello di idratazione ottimale, evitando così uno stato di sofferenza da secchezza. Di conseguenza, risulterebbe facilitata la penetrazione in profondità della fosfatidilcolina NON idrogenata e del desossicolato, e quindi la loro azione lipolitica per la dissoluzione delle adiposità localizzate. The compositions object of the present invention show results that cannot be explained with the simple sum of the effects recorded with the separate administration of the single components. This appears apparently due to the indirect moisturizing action of hydrogenated phosphatidylcholine. This substance, unlike NON-hydrogenated phosphatidylcholine, preserves and stabilizes the surface hydrolipidic mantle of the skin, thus minimizing the loss of water by evaporation, guaranteeing the skin an optimal level of hydration, thus avoiding a state of suffering from dryness. Consequently, the deep penetration of NON-hydrogenated phosphatidylcholine and deoxycholate, and therefore their lipolytic action for the dissolution of localized adiposities, would be facilitated.
La migliore sinergia sembra ottenersi quando : The best synergy seems to be obtained when:
- la fosfatidilcolina NON idrogenata ha una - NON-hydrogenated phosphatidylcholine has a
concentrazione tra lo 0.3 ed il 3%, preferibilmente dell' 1% concentration between 0.3 and 3%, preferably 1%
- la fosfatidilcolina idrogenata ha una concentrazione tra lo 0.1 ed il 10%, preferibilmente dello 0.5% - hydrogenated phosphatidylcholine has a concentration between 0.1 and 10%, preferably 0.5%
- il desossicolato. ha una concentrazione non inferiore allo 0.2%, preferibilmente dello 0.5%. - the deoxycholate. it has a concentration of not less than 0.2%, preferably 0.5%.
Parte 6 ; il dettaglio dell’ invenzione Part 6; the detail of the invention
Le composizioni della presente invenzione saranno formulate in modo. da essere adatte ad una applicazione topica sulla cute. The compositions of the present invention will be formulated in a manner. to be suitable for topical application on the skin.
Si presenteranno in forma di gel creme, soluzioni o sospensioni, utilizzando tecniche ed eccipienti convenzionali e comunque compatibili con l uso. Creams, solutions or suspensions will be presented in gel form, using conventional techniques and excipients and in any case compatible with use.
Si riporta qui di seguito un esempio di formulazione secondo , l invenzione. An example of the formulation according to the invention is reported below.
ESEMPIO EXAMPLE
Formulazione in crema Cream formulation
INGREDIENTE QUANTITÀ % IN PESO Liporeductyl 5 Fosfatidilcolina _ 1 Fosfatidilcolina idrogenata 0.5 INGREDIENT AMOUNT% BY WEIGHT Liporeductyl 5 Phosphatidylcholine _ 1 Hydrogenated Phosphatidylcholine 0.5
Sodio desossicolato 0.5 Sodium deoxycholate 0.5
Eccipienti cosmetici q.b. Cosmetic excipients q.s.
Acqua q b. a 100 Water q b. to 100
Parte 7 : il funzionamento dell ’ invenzione Part 7: the operation of the invention
Applicare sulla pelle e massaggiare energicamente fino a totale assorbimento, preferibilmente al mattino, prima di iniziare fa giornata, e.la sera, immediatamente prima di coricarsi. Apply to the skin and massage vigorously until completely absorbed, preferably in the morning, before starting the day, and in the evening, immediately before going to bed.
Il trattamento va continuato fino al raggiungimento di un risultato soddisfacente The treatment should be continued until a satisfactory result is achieved
Parte 8 : chiusura Part 8: closing
Il trovato così concepito è suscettibile di modifiche e varianti, purché rientranti nell ambiti del concetto inventivo. Tutti i dettagli sono infine sostituibili con altri tecnicamente equivalenti. The invention thus conceived is susceptible of modifications and variations, provided they fall within the scope of the inventive concept. Finally, all the details can be replaced with other technically equivalent ones.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001862A ITMI20081862A1 (en) | 2008-10-21 | 2008-10-21 | COMPOSITION FOR TOPIC USE FOR THE TREATMENT OF LOCALIZED ADIPOSITIES AND RELATED IMAGINATIONS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001862A ITMI20081862A1 (en) | 2008-10-21 | 2008-10-21 | COMPOSITION FOR TOPIC USE FOR THE TREATMENT OF LOCALIZED ADIPOSITIES AND RELATED IMAGINATIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20081862A1 true ITMI20081862A1 (en) | 2010-04-22 |
Family
ID=41009012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT001862A ITMI20081862A1 (en) | 2008-10-21 | 2008-10-21 | COMPOSITION FOR TOPIC USE FOR THE TREATMENT OF LOCALIZED ADIPOSITIES AND RELATED IMAGINATIONS |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | ITMI20081862A1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739623A1 (en) * | 1994-01-19 | 1996-10-30 | Taisho Pharmaceutical Co. Ltd | Dermatologic composition |
| WO2000045774A1 (en) * | 1999-02-04 | 2000-08-10 | Phares Pharmaceutical Research Nv | Membrane lipid compositions |
| CA2381571A1 (en) * | 1999-08-25 | 2001-03-01 | Merckle Gmbh | Phospholipid gel |
| WO2004108140A1 (en) * | 2003-06-05 | 2004-12-16 | Doosan Corporation | Composition for inhibiting differentiation or growth of fat cells |
| US20060127468A1 (en) * | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
| WO2006116486A2 (en) * | 2005-04-26 | 2006-11-02 | P.A. Holdings Llc | Composition and method for reducing the appearance for cellulite |
| WO2007135703A2 (en) * | 2006-05-18 | 2007-11-29 | Vitrupharma S.R.L. | Patch for the treatment of the cellulite and localized adiposity |
-
2008
- 2008-10-21 IT IT001862A patent/ITMI20081862A1/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739623A1 (en) * | 1994-01-19 | 1996-10-30 | Taisho Pharmaceutical Co. Ltd | Dermatologic composition |
| WO2000045774A1 (en) * | 1999-02-04 | 2000-08-10 | Phares Pharmaceutical Research Nv | Membrane lipid compositions |
| CA2381571A1 (en) * | 1999-08-25 | 2001-03-01 | Merckle Gmbh | Phospholipid gel |
| WO2004108140A1 (en) * | 2003-06-05 | 2004-12-16 | Doosan Corporation | Composition for inhibiting differentiation or growth of fat cells |
| US20060127468A1 (en) * | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
| WO2006116486A2 (en) * | 2005-04-26 | 2006-11-02 | P.A. Holdings Llc | Composition and method for reducing the appearance for cellulite |
| WO2007135703A2 (en) * | 2006-05-18 | 2007-11-29 | Vitrupharma S.R.L. | Patch for the treatment of the cellulite and localized adiposity |
Non-Patent Citations (1)
| Title |
|---|
| ROTUNDA A M ET AL: "Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution", DERMATOLOGIC SURGERY, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 30, no. 7, 1 July 2004 (2004-07-01), pages 1001 - 1008, XP002331643, ISSN: 1076-0512 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI652066B (en) | Peptide for rejuvenating skin and method of use thereof | |
| KR100924476B1 (en) | Topical glycopyrrolate product | |
| US20100247693A1 (en) | Cosmetic formulation to treat rosacea telangiectasia | |
| TW200526260A (en) | Cosmetic composition and methods | |
| KR102468524B1 (en) | Use of Mussel Adhesive Protein Products in the Treatment and Prevention of Melanin Associated Diseases | |
| US9789099B2 (en) | Cosmetic or dermatological preparation for prophylaxis and/or treatment of atopic dermatitis | |
| PL214285B1 (en) | Use of purslane to treat facial wrinkles | |
| CA2761732C (en) | Composition for preventing hair loss or for stimulating hair growth | |
| US20110236503A1 (en) | Topical Skincare Composition | |
| EA038613B1 (en) | Blended formulations | |
| ES2684519T3 (en) | Dermatological composition based on algae and olive leaf extracts | |
| US20120064020A1 (en) | Novel composition | |
| US20200030398A1 (en) | Skin care composition | |
| AU2009273211A1 (en) | Transdermal pharmaceutical compositions comprising danazol | |
| JP6628488B2 (en) | External gel composition | |
| ES2606233T3 (en) | Compositions for the treatment of rosacea comprising chitosan and a dicarboxylic acid amide | |
| ES2278998T3 (en) | COMPOSITION BASED ON A DIOSGENINE ESTER APPLICABLE BY VIA TOPICA. | |
| ITMI20081862A1 (en) | COMPOSITION FOR TOPIC USE FOR THE TREATMENT OF LOCALIZED ADIPOSITIES AND RELATED IMAGINATIONS | |
| ES2939257T3 (en) | Peptide with skin whitening activity and use thereof | |
| ES2322122B1 (en) | COSMETIC COMPOSITION FOR THE CARE AND REPAIR OF TELANGIECTASIAS. | |
| KR101626473B1 (en) | Composition for external application to the skin containing cyclohexane dicarboxylic acid derivatives | |
| ITMI20090145A1 (en) | COMPOSITION FOR TOPIC USE FOR THE TREATMENT OF LOCALIZED ADIPOSITIES AND RELATED IMAGINATIONS | |
| KR101661694B1 (en) | Low irritating composition for skin whitening comprising hydroquinone | |
| KR102125790B1 (en) | Multifunctional mask pack and preparation method thereof | |
| JP6659735B2 (en) | Use of potassium hydroxide in the treatment of actinic keratosis |